Invited Faculty
  • Peter E. Lipsky
    AMPEL BioSolutions
    USA
  • After receiving his medical degree from the New York University School of Medicine and completing residency training at the Strong Memorial Hospital in Rochester, New York, Dr Lipsky became a Clinical Associate at the National Institute of Allergy and Infectious Diseases, NIH in 1971. For the next four years, Dr Lipsky received clinical training in rheumatology, allergy and infectious diseases and carried out research on the role of antigen presenting cells in initiating and regulating immune responses. In1975, Dr Lipsky moved to the University of Texas Southwestern Medical Center at Dallas, initially as an Instructor in Internal Medicine and progressing to the rank of Professor of Internal Medicine and Microbiology in 1983. Later appointments at Southwestern Medical Center included Director of the Harold C Simmons Arthritis Research Center, Co-Director of the Immunology Graduate Program, and Director of the Rheumatic Disease Division of the Department of Internal Medicine. Dr Lipsky was named the Harold C Simmons Professor in Arthritis Research in 1995. From 1999-2004, he served as the Director of the Intramural Research Program at the National Institute of Arthritis and Musculoskeletal and Skin Diseases and also as the founder and the Chief of the Autoimmunity Branch in NIAMS. Since 2013, Dr Lipsky has been founder and CEO of AMPEL BioSolutions, a company devoted to developing methods to support precision medicine for patients with systemic lupus erythematosus and other autoimmune and inflammatory diseases.

    Dr Lipsky’s major research interests are related to the immune basis of autoimmune and inflammatory diseases. Dr Lipsky is internationally recognized for his research, particularly his work on T cell–macrophage interactions, the mechanisms of immune cell activation, the role of T cell and B cell subsets and their products in autoimmune diseases, and for his role in the development of novel therapeutics for rheumatoid arthritis and systemic lupus erythematosus, including monoclonal antibodies. Dr Lipsky has had the distinct pleasure of being involved in the training of more than 150 post-doctoral fellows and students, many of whom have developed into leadership roles in international rheumatology and immunology. Dr Lipsky served on the Board of Directors of the ACR and also as the chair of the Medical and Scientific Committee of the Arthritis Foundation. He is a member of the American Society for Clinical Investigation and the Association of American Physicians, and is a past president of the Clinical Immunology Society. He is the past Editor-in-Chief of the Journal of Immunology (1992–1997), a founding editor of Arthritis Research and Therapy and also the former editor-in-chief of Nature Reviews Rheumatology. He is an author of more than 650 research articles.

    Dr Lipsky has been awarded numerous prizes, including the 2001 Carol Nachman Prize and the 2002 American College of Rheumatology Distinguished Investigator Award. In 2002, the Arthritis Foundation awarded Dr Lipsky the prestigious Lee Howley prize for his research contributions, and in 2008 he became a Master of the American College of Rheumatology.
    Research & Clinical Focus

    Bioinformatics

    SLE

    Personalized Medicine

    Transcriptomics

    Genetics

    • Date Time Room Session Title Lecture Title
    May 19 17:20-17:40 Room Grand Ballroom 101 [Concurrent Session 8] Omics and Breakthrough Technology New insights into SLE from machine learning of transcriptomic data